New MS drugs on the horizon

A new multiple sclerosis therapy may be available in Australia soon, depending on the outcome of regulatory approval processes currently underway.

At its meeting this month the Pharmaceutical Benefits Advisory Committee is considering the listing of daclizumab (Zinbryta), a humanised monoclonal antibody for the treatment of relapsing remitting disease.

At the same time the drug has been filed with the